Unravelling intracellular immune dysfunctions in chronic fatigue syndrome: Interactions between protein kinase R activity, RNase L cleavage and elastase activity, and their clinical relevance

In Vivo

Volumn 22, Issue 1, 2008, Pages 115-122

  Meeus, Mira ^a,b   Nijs, Jo ^a,b   McGregor, Neil ^c   Meeusen, Romain ^a   De Schutter, Guy ^a   Truijen, Steven ^b   Frémont, Marc ^d   Van Hoof, Elke ^a   De Meirleir, Kenny ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b Hogeschool Antwerpen   (Belgium)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d R E D LABORATORIES   (Belgium)

Author keywords

Chronic fatigue syndrome; Daily functioning; Elastase; Nitric oxide; Protein kinase R; RNase L

Indexed keywords

ELASTASE; PROTEIN KINASE R; RIBONUCLEASE L;

ADULT; ARTICLE; BLOOD SAMPLING; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CORRELATIONAL STUDY; DAILY LIFE ACTIVITY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME DEGRADATION; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; PROTEIN PROTEIN INTERACTION; QUESTIONNAIRE; SYMPTOM;

EID: 40749083947     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Holmes GP, Kaplan JE, Gantz NM, Komaroff AL, Schonberger LB, Strauss SE, Jones JF, Dubois RE, Cunningham-Rundles C, Pawha S, Tosato G, Zegans LS, Purtilo DT, Brown N, Schooley RT and Brus I: Chronic Fatigue Syndrome: a working case definition. Ann Intern Med 108: 387-389, 1988.
2. Fukuda K Strauss SE, Hickie I, Sharpe MC, Dobbins JG and Komaroff AL, The International Chronic Fatigue Syndrome Study Group: The Chronic Fatigue Syndrome, a comprehensive approach to its definition and study. Ann Intern Med 121: 953-959, 1994.
3. De Meirleir K, De Becker P, Nijs J, Peterson DL, Nicolson G, Patarca-Montero R and Englebienne P: CFS etiology, the immune system, and infection. In: Chronic Fatigue Syndrome: A Biological Approach. Englebienne P and De Meirleir K (eds.). Florida, Boca, pp. 201-228, 2002.
4. Buchwald D and Komaroff AL.: Review of laboratory findings for patients with Chronic Fatigue Syndrome. Rev Infect Dis 13: S12-S8, 1991.
5. Theorell T, Blomkvist V, Lindh G and Evengard B: Critical life events, infections, and symptoms during the year preceding Chronic Fatigue Syndrome (CFS): an examination of CFS patients and subjects with a nonspecific life crisis. Psychosom Med 61: 304-310, 1999.
6. Suhadolnik RJ, Reichenbach NL, Hitzges P, Sobol RW, Peterson DL, Henry B, Ablashi DV, Müller WEG, Schröder HC, Carter WA and Strayer DR: Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with Chronic Fatigue Syndrome. Clin Infect Dis 18: S96-104, 1994.
7. Suhadolnik RJ, Peterson DL, O'Brien K, Cheney PR, Herst RV, Reichenbach NL, Kon N, Horvath SE, Iacono KT, Adelson ME, De Meirleir K, De Becker P, Charubala R and Pfleiderer W: Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in Chronic Fatigue Syndrome. J Interferon Cytokine Res 17: 377-385, 1997.
8. Suhadolnik RJ, Peterson DL, Cheney PR, Horvath SE, Reichenbach NL, O'Brien K, Lombardi V, Welsch S, Furr EG, Charubala R and Pfleiderer W: Biochemical dysregulation of the 2-5A synthetase/RNase L antiviral defense pathway in Chronic Fatigue Syndrome. J Chronic Fatigue Syndr 5: 223-242, 1999.
9. De Meirleir K, Bisbal C, Campine I, De Becker P, Salehzada T, Demettre E and Lebleu B: A 37 kDa 2-5A binding protein as a potential biochemical marker for Chronic Fatigue Syndrome. American J Med 108: 99-105, 2000.
10. Shetzline SE, Martinand C, Reichenbach NL, Buletic Z, Lebleu B, Pfleiderer W, Charubala R, De Meirleir K, De Becker P, Peterson DL, Herst CV, Englebienne P and Suhadolnik RJ: Structural and functional features of the 37-kDa 2-5A-dependent RNase L in chronic fatigue syndrome. J Interferon Cytokine Res 22: 443-456, 2002.
11. Demettre E, Bastide L, D'Haese A, De Smet K, De Meirleir K, Tiev KP, Englebienne P and Lebleu B: Ribonuclease L proteolyse in peripheral blood mononuclear cells of chronic fatigue syndrome patients. J Biol Chem 277: 35746-35751, 2002.
12. Englebienne P, Herst CV, De Smet K, D'Haese A and De Meirleir K: Interactions between RNase L ankyrin-like domain and ABC transporters as a possible origin for pain, ion transport, CNS and immune disorders of chronic fatigue immune dysfunction syndrome. J Chronic Fatigue Syndr 8: 83-89, 2001.
13. Shetzline SE and Suhadolnik RJ: Additions and Corrections - Characterization of a 2',5'-oligoadenylate (2-5A)-dependent 37-kDa RNase L. Azido photoaffinity labeling and 2-5A-dependent activation. J Biol Chem 276: 23707-23711, 2001.
14. Englebienne P: RNase L in health and disease-What did we learn recently? J Chronic Fatigue Syndr 11: 97-109, 2003.
15. Chaudhuri A and Behan PO: Neurological dysfunction in chronic fatigue syndrome. J Chronic Fatigue Syndr 6: 51-68, 2000.
16. Watson WS, McMillan DC, Chaudhuri A and Behan PO: Increased resting expenditure in the Chronic Fatigue Syndrome. J Chronic Fatigue Syndr 4: 3-14, 1998.
17. Nijs J, Demanet C, McGregor NR, De Becker P, Verhas M, Englebienne P and De Meirleir K: Monitoring a hypothetical channelopathy in Chronic Fatigue Syndrome: preliminary observations. J Chronic Fatigue Syndr 11: 117-133, 2003.
18. Iordanov MS, Wong J, Bell JC and Magun BE: Activation of NF-ΚB by double-stranded RNA (dsRNA) in the absence of protein kinase R and RNase L demonstrates the existence of two separate dsRNA-triggered antiviral programs. Mol Cell Biol 21: 61-72, 2001.
19. Uetani K, Der SD, Zamanian-Daryoush M, De La Motte C, Lieberman BY, Williams BRG and Erzurum SC: Central role of double-stranded RNA-activated protein kinase in microbial induction of nitric oxide. J Immunol 165: 988-996, 2000.
20. Paludan SR, Ellerman-Eriksen S and Mogensen SC: NF-ΚB activation is responsible for the synergistic effect of herpes simplex virus type 2 infection on interferon-γ-induced nitric oxide production in macrophages. J Gen Virol 79: 2785-2793, 1998.
21. Pall ML: Elevated, sustained peroxynitrite levels as the cause of Chronic Fatigue Syndrome. Med Hypothes 54: 115-125, 2000.
22. Pall ML: Elevated nitric oxide/peroxynitrite theory of multiple sensitivity: central role of N-methyl-D-aspartate receptors in the sensitivity mechanism. Environ Health Perspect 111: 1461-1464, 2003.
23. Kurup RK and Kurup PA: Hypothalamic digoxin, cerebral chemical dominance and myalgic encephalomyelitis. Int J Neurosc 113: 683-701, 2003.
24. Pall ML: Common etiology of posttraumatic stress disorder, fibromyalgia, Chronic Fatigue Syndrome and multiple chemical sensitivity via elevated nitric oxide/peroxynitrite. Med Hypothes 57: 139-145, 2001.
25. Nijs J, Meeus M, McGregor NR, Meeusen R, De Schutter G, Van Hoof E and De Meirleir K: Chronic fatigue syndrome: exercise performance related to immune dysfunction. Med Sci Sports Exerc 37: 1647-1654, 2005.
26. Ware JE, Snow KK, Kosinski M and Gandek B: SF-36 Health Survey Manual and Interpretation Guide. Boston, The Health Institute, 1993.
27. McHorney CA, Ware JE, Lu JFR and Sherbourne CD: The MOS 36-item Short Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patients groups. Medical Care 32: 40-66, 1994.
28. Wells KB, Stewart A, Hays R, Burnam MA, Rogers W, Daniels M, Berry S, Greenfield S and Ware J: The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 262: 914-919, 1989.
29. Nijs J, Vaes P, Van Hoof E, De Becker P, McGregor NR and De Meirleir K: Activity limitations and participation restrictions in patients with chronic fatigue syndrome - construction of a disease specific questionnaire. J: Chronic Fatigue Syndr 10: 3-23, 2002.
30. Nijs J, Vaes P, McGregor NR, Van Hoof E and De Meirleir K: Psychometric Properties. of the Dutch Chronic Fatigue Syndrome - Activities and Participation Questionnaire (CFS-APQ). Phys Ther 83: 444-454, 2003.
31. Nijs J, De Becker P and De Meirleir K: Gebruik van vragenlijsten bij de kinesitherapeutische evaluatie van patiënten met het chronisch vermoeidheidssyndroom. In: Jaarboek Fysiotherapie Kinesitherapie. Smets-Engelsman BCM, Vaes P, Verhaegen AP, Scholten-Peeters GGM (eds.). Houten/Diegem, Bohn Stafleu Van Loghum, pp. 77-107, 2003.
32. Nijs J, De Meirleir K, Wolfs S and Duquet W: Disability evaluation in chronic fatigue syndrome: associations between exercise capacity and activity limitations/participation retsrictions. Clin Rehabil 18: 139-148, 2004.
33. Tiev MP, Demettre E, Ercolano P, Bastide L, Lebleu B and Cabane J: RNase L levels in peripheral blood mononuclear cells: 37-kilodalton/ 83-kilodalton isoform ratio is a potential test for chronic fatigue syndrome. Clin Diagn Lab Immunol 10: 315-316, 2003.
34. Saelens X, Kalai M and Vandenabeele P: Translation inhibition in apoptosis: caspase-dependent PKR-activation and eIF2-alpha phosphorylation. J Biol Chem 276: 41620-41628, 2001.
35. Bauer JA, Morrison BH, Grane RW, Jacobs BS, Dabney S, Gamero AM, Carnevale KA, Smith DJ, Drazba J, Seetharam B and Lindner DJ: Effects of interferon beta on transcobalamin II-receptor expression and antitumor activity of nitrosylcobalamin. J Nat Cancer Inst 94: 1010-1019, 2002.
36. Itoh Y, Ma FH, Hoshi H, Oka M, Noda K, Ukai Y, Kojima H, Nagano T and Toda N: Determination and bioimaging method for nitric oxide in biological specimens by diaminofluorescein fluorometry. Anal Biochem 287: 203-209, 2000.
37. Kojima H, Urano Y, Kikuchi K, Higuchi T, Hirata Y and Nagano T: Fluorescent indicators for imaging nitric oxide production. Angew Chem Int Ed Engl 38: 3209-3212, 1999.
38. Greenberger PA: Immunologic aspects of lung diseases and cystic fibrosis. J Am Med Ass 278: 1924-1930, 1997.
39. Senior RM, Griffin GL, Fliszar CJ, Shapiro SD, Goldberg GI and Welgus HG: Human 92- and 72-kilodalton type IV collagenase are elastases. J Biol Chem 266: 7870-7875, 1991.
40. Rowbottom D, Keast D, Pervan Z and Morton A: The physiological response to exercise in Chronic Fatigue Syndrome. J Chronic Fatigue Syndr 4: 33-49, 1998.
41. Friman G and Ilback NG: Acute infection: metabolic responses, effects on performance, interaction with exercise, and myocarditis. Int J Sports Med 19: S172-182, 1998.
42. Chérin P: Muscle, fatigue, sport et infection. Rev Méd Interne. 20: 794-803, 1999.
43. Snell CR, Vanness JM, Strayer DR and Stevens SR: Physical performance and prediction of 2-5A synthetase/RNase L antiviral pathway activity in patients with chronic fatigue syndrome. In Vivo 16: 107-109, 2002.
44. De Becker P, McGregor NR and De Meirleir K: A definition-based analysis of symptoms in a large cohort of patients with chronic fatigue syndrome. J Intern Med 250: 234-240, 2001.
45. Fischler B, Dendale P, Michiels V, Cluydts R, Kaufman L and De Meirleir K: Physical fatigability and exercise capacity in Chronic Fatigue Syndrome: association with disability, somatization and psychopathology. J Psychosom Res 42: 369-378, 1997.
46. Riley MS, O'Brien CJ, Mccluskey DR, Bell NP and Nicholls DP: Aerobic work capacity in patients with Chronic Fatigue Syndrome. BMJ 301: 953-956, 1990.
47. Fulcher KY and White PD: Strength and physiological response to exercise in patients with Chronic Fatigue Syndrome. J Neurol Neurosurg Psychiatry 69: 302-307, 2000.
48. 2 consumption and physical activity in patients with chronic fatigue. Am J Physiol Heart Circ Physiol 282: H66-71, 2002.
49. De Becker P, Roeykens J, Reynders M, McGregor NR and De Meirleir K: Exercise capacity in Chronic Fatigue Syndrome patients. Arch Intern Med 160: 3270-3277, 2000.
50. Jason LA, Richman JA, Rademaker AW, Jordan KM, Plioplys AV, Taylor RR, McCready W, Huang CF and Plioplys S: A community-based study of chronic fatigue syndrome. Arch Intern Med 159: 2129-2137, 1999.